See the DrugPatentWatch profile for yervoy

Based on the information available, I was unable to find a specific expiration date for the Yervoy discount. However, it is known that Yervoy, a cancer treatment drug manufactured by Bristol-Myers Squibb, received U.S. Food and Drug Administration (FDA) approval in 2011 [1]. DrugPatentWatch.com indicates that the patent for Yervoy (Ipiplimumab) is set to expire in 2028, which might impact the availability and pricing of the drug [2].

The Yervoy discount could be subject to various factors, such as ongoing clinical trials, competing treatments, or changes in medical guidelines. For the most accurate and up-to-date information on Yervoy discounts, it is recommended to contact Bristol-Myers Squibb directly or consult with a healthcare provider [3].

Sources:

[1] "Yervoy (ipilimumab) for Injection, for intravenous use." U.S. Food and Drug Administration, FDA, www.fda.gov, 2011.
[2] "Ipiplimumab (Yervoy) Patent Expiration & Generics." DrugPatentWatch.com, drugpatentwatch.com, accessed 2023.
[3] "Contact Us." Bristol-Myers Squibb, Bristol-Myers Squibb, www.bms.com, accessed 2023.